Colon carcinoma and immunologic phenomena

A new approach in the immunotherapy of carcinoma of the colon and rectum

Although the therapy of carcinoma of the colon and rectum has been investigated, little progress has been made in prolonging the survival in these patients. Specific active immunotherapy may provide the answer. Previous investigators have shown that colorectal cancer elicits an immune response and may be susceptible to immunologic manipulation. My laboratory has shown that a live vaccinia virus-augmented (vaccinia oncolysate) tumor cell vaccine is safe and may be worthwhile in the surgical adjuvant treatment of colorectal cancer. Nine patients with advanced cancer were treated. 0/9 showed adverse effect and 3/9 showed lack of progression of disease. Randomized prospective trials are now underway.

Changes in composition of mucin in the mucosa adjacent to carcinoma of the colon as compared with the normal: a biochemical investigation

Fifteen surgical specimens from patients with carcinoma of the colon and rectum were studied. Scrapings from normal mucosa distant from the tumour and from macroscopically normal mucosa adjacent to the tumour (;transitional') were used for chemical estimation of hexosamines, sialic acid, and proteins. The presence of hexosamines and sialic acid was confirmed in both normal and transitional mucosa. Transitional mucosa showed increased levels of total hexosamines and sialic acid as compared with the normal and this was accompanied by an increase in neuraminidase-sensitive sialic acids. The present data have been compared with previous histochemical and autoradiographic studies and it is suggested that the changes described in the transitional mucosa are transformations representing an early stage of carcinogenesis.